Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Recruiting
N/A
Interventional Study
Relapsing Remitting Multiple Sclerosis (RRMS)
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 220 (estimated)
- Sponsor
- Glostrup University Hospital, Copenhagen · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can ben…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Women and men ≥18 and ≤65 years of age
* Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates)
* Routinely treated and monitored for MS
* Speak and read Danish
* Deemed physically and mentally able to participate in this study
Exclusion Criteria:
* A…
Contacts
Jette Lautrup Frederiksen, MD, dr.med, professor
+4538633041
jette.lautrup.battistini@regionh.dk
CONTACT